Chase Investment Counsel’s Catalyst Pharmaceutical CPRX Stock Holding History

Chase Investment Counsel’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.89M	Hold	60,000	–	–	0.4%	52
2026 Q1	$1.49M	Hold	60,000	–	–	0.39%	64
2025 Q4	$1.4M	Hold	60,000	–	–	0.39%	58
2025 Q3	$1.18M	Buy	60,000 +6,000	+11%	+$123K	0.35%	64
2025 Q2	$1.17M	Hold	54,000	–	–	0.37%	61
2025 Q1	$1.31M	Hold	54,000	–	–	0.48%	57
2024 Q4	$1.13M	Buy	+54,000	New	+$1.16M	0.36%	64

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Chase Investment Counsel's CPRX Position: Q2 2026 in Review

Chase Investment Counsel held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 60,000 shares worth $1.89M. The position accounts for 0.4% of the portfolio, ranked #52.

Chase Investment Counsel first reported a position in CPRX in Q4 2024 and has held it in 7 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Chase Investment Counsel held 60,000 shares of Catalyst Pharmaceutical worth $1.89M as of Q2 2026.
Chase Investment Counsel left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up 0.4% of Chase Investment Counsel's portfolio in Q2 2026, its #52 holding.
Chase Investment Counsel first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Chase Investment Counsel's 13F filing for Q2 2026, filed 6 Aug 2026.